NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	50.75M 43.72M 40.27M 37.73M 70.84M 4.83B 71.7M 477M 185M 2.35B 190M 186M 8.12B	P/E Ratio 2024 *	-	P/E Ratio 2025	-2.81x
Enterprise Value	48.9M 42.13M 38.81M 36.36M 68.26M 4.65B 69.09M 459M 179M 2.26B 184M 180M 7.82B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	35.62%	Yield 2024 *	-	Yield 2025	-

27/05	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
27/05	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
01/05	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
30/04	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
29/04	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
20/04	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
02/04	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
09/03	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE
12/01	Newcelx Ltd. Announces Positive Results from International Collaborative Study	CI
06/01	NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board	CI
17/11	NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory Board	CI
07/11	NewcelX Ltd. Announces Chief Financial Officer Changes, Effective December 10, 2025	CI
06/11	NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory Board	CI

27/05	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL
30/04	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026	AQ
20/04	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference	GL
01/04	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing	GL
09/03	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-0.78%	+153.00%	-	-	17.39M
LONZA GROUP AG	-0.35%	+0.97%	-13.80%	-13.25%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+279.08%	+501.52%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+15.66%	-15.65%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-1.91%	+24.64%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+12.97%	+20.22%	25.08B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+56.69%	+113.41%	13.35B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.23%	+7.63%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.89%	+74.92%	12.11B
Average	+0.63%	+1.45%	+57.60%	+89.18%	23.61B
Weighted average by Cap.	+1.05%	+1.48%	+57.30%	+96.08%

	2024	2025
Net sales	-	-
Net income	-26.55M -22.87M -21.07M -19.74M -37.06M -2.53B -37.51M -249M -96.97M -1.23B -99.64M -97.52M -4.25B	-8.3M -7.15M -6.59M -6.17M -11.59M -789M -11.73M -77.97M -30.31M -384M -31.15M -30.48M -1.33B
Net Debt	7.35M 6.33M 5.83M 5.46M 10.26M 699M 10.38M 69.02M 26.83M 340M 27.57M 26.98M 1.17B	-1.85M -1.59M -1.46M -1.37M -2.58M -176M -2.61M -17.34M -6.74M -85.37M -6.93M -6.78M -295M

Kadimastem Stock OTC Markets

Stocks

KMSTF

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem

Latest news : Kadimastem

Analysts' recommendations: Kadimastem

Press Releases: Kadimastem

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile